Same patient. Same blood draw.
Different biology.
Two illustrative systems. One variable changes: measured platelet recovery.
You use the same 25 mL collection protocol for nearly every patient.
The workflow is standardized. Is the delivered biology?
Before the centrifuge begins spinning, the available platelet population has already been determined by two variables: the patient’s baseline platelet count and the volume of blood collected.
The system must then preserve and recover that population through anticoagulation, separation, aspiration and transfer. Platelets left in upper plasma, near the buffy coat, within the erythrocyte fraction or inside processing components do not reach the treatment site.
Harvesting a smaller plasma volume may produce a higher concentration while still delivering fewer total platelets. A larger harvest may lower the average concentration while increasing the injected dose.
None of these observations make a 25 mL system inherently inadequate. They determine whether the system can produce, verify and adapt the intended dose for the patient being treated.
Which variables does your PRP system actually measure, and which are built into the protocol as assumptions?
A reported dose depends on how the baseline count, anticoagulant, recovery percentage, harvest boundary and final injected volume were measured or estimated.
Platelet dose is often presented as a single number. In practice, that number depends on a chain of measurements, definitions and assumptions.
Was the patient’s baseline platelet count known?
A fixed collection volume cannot produce a predictable dose when the platelet population entering the system is unknown. Two patients using the same 25 mL protocol may begin with substantially different numbers of available platelets.
Has anticoagulant dilution been accounted for correctly?
Anticoagulant adds platelet-free fluid to the collected blood. This changes measured concentration without changing the number of platelets originally collected.
The important audit question is not whether anticoagulant causes dilution. It is whether the manufacturer’s recovery and concentration calculations consistently use pre-dilution or post-dilution values.
What does the reported recovery percentage include?
A recovery percentage may appear precise while leaving the testing method unclear. The reported value may depend on where the final sample was collected, how much plasma was harvested and whether all final product fractions were included.
Platelets may remain in upper plasma, near the buffy coat or within the erythrocyte fraction.
Aspiration depth, harvest volume, valves, interfaces and system geometry may change the final recovery.
Does harvest volume change only concentration, or dose too?
Plasma closest to the buffy coat may have the highest platelet concentration. Additional platelets may still remain farther into the overlying plasma.
May capture the region with the highest average platelet concentration.
Higher concentration may result Additional platelets may remain above the harvest.May collect platelets extending farther into the plasma column.
Average concentration may decrease Total injected platelet dose may increase.Which variables are measured and which are assumed?
The dose equation is not difficult. The uncertainty lies in the variables used to populate it.
A fixed 25 mL protocol may be entirely appropriate. The audit question is whether the system can identify when it is not.
One centrifuge runs quietly. Another sounds like a small rocket ship.
Most clinicians have heard the difference. Few have considered what that difference may mean for the cells being processed.
Separation is only the visible outcome. During processing, blood is exposed to acceleration, deceleration, vibration, fluid movement and repeated mechanical loading. Rotor balance, tube fit, braking behavior and centrifuge stability all contribute to that mechanical environment.
Platelets are mechanosensitive cells. Mechanical forces influence their behavior throughout the cardiovascular system, and platelets are not passive passengers during centrifugation. They are living cells moving through an engineered environment that can differ from one system to another.
A protocol operating at 2,300 × g exposes cells to substantially greater centrifugal acceleration than one operating at 1,500 × g. Higher force may be appropriate when it serves a demonstrated purpose, but recovery alone does not describe everything the cells experienced during processing.
Visible vibration does not prove platelet injury. It does, however, indicate that the rotating system is transmitting additional motion beyond smooth radial acceleration. That observation deserves investigation rather than automatic acceptance as normal.
The centrifuge is more than a separator. It is the first engineered mechanical environment your therapeutic cells experience.
You finish processing the PRP and instinctively hold the syringe up to the light.
Sometimes it is bright gold. Sometimes it is pink, red or unexpectedly hazy. Most clinicians notice the difference. Fewer stop to investigate what produced it.
The blood draw is one possible source, but it is not the only one. Appearance may reflect the patient’s circulating blood, collection technique, vacuum or aspiration forces, centrifuge mechanics, cellular gradient stability, aspiration depth or the internal design of the PRP system itself.
Bright gold plasma generally suggests limited visible erythrocyte contamination, but color alone does not establish platelet dose, leukocyte composition or platelet function. A visually attractive product still requires measurement.
Pink plasma may reflect free hemoglobin released after red-cell membrane disruption. Potential contributors include a difficult venipuncture, excessive negative pressure during syringe aspiration, excessive vacuum, forceful transfer, transport trauma or mechanical stress during centrifugation.
A visibly red preparation more often raises a different question: whether intact erythrocytes crossed into the final product. Aspiration depth, poor visualization, disturbed interfaces, mechanical valves, narrow collection windows or system geometry may all contribute.
Hazy or cloudy plasma may reflect the patient’s biology rather than a device failure. Lipemia following a high-fat meal is one possible cause and should be distinguished from hemolysis, cellular carryover or processing-related turbidity.
Appearance is not a complete quality measurement. It is an immediate quality-control observation that can help identify which part of the process deserves investigation.
You position the aspiration tip near the buffy-coat interface and assume the intended cells are entering the syringe.
But the collection boundary was created before aspiration began.
Centrifugal force, spin duration, acceleration, braking, rotor geometry and tube design determine how blood components migrate and where the cellular interfaces form. Aspiration technique then determines which portion of that distribution reaches the syringe.
Proximity to the buffy coat may increase access to platelet-rich plasma and selected cellular populations, but proximity alone does not establish what was recovered. The intended cells must first have been placed within the region made available for collection.
Aspiration depth, interface visibility, port position, resuspension and operator technique may each change the final platelet and leukocyte profile. Two clinicians using the same device may therefore collect different products unless the workflow is appropriately controlled.
In systems using a gel or another physical separator, the density and movement of that barrier become part of the cellular-selection process. The barrier may improve consistency, but it also helps determine which cells remain accessible above it.
A final platelet count confirms that platelets are present. It does not, by itself, establish that their structure, activation state and biological function were preserved throughout processing.
Does your system separate the cellular population you intend to deliver, or simply the population its design makes easiest to collect?
A cell count can establish how many platelets reached the sample. Evaluation of activation state, structural integrity and function requires additional testing.
The final cellular profile is not created by aspiration alone. It is the product of the complete separation and collection pathway.
How were centrifugal force and spin duration selected?
Centrifugal force and time work together to determine how far and how quickly blood components migrate. A protocol using a higher relative centrifugal force for a shorter period may create a different cellular distribution than one using a lower force for a longer period.
The protocol should be selected to produce a defined and reproducible distribution, not merely a visible separation.
Recovery should be considered alongside platelet activation, structural integrity and functional testing.
A visible buffy coat confirms that a cellular interface formed. It does not independently establish that the intended platelet population is concentrated there, that the cells remain functionally preserved or that the interface is accessible to the collection pathway.
What cellular population is actually present at the collection boundary?
The visible interface is a region, not a single uniform layer. Platelets, monocytes, neutrophils and erythrocytes may occupy overlapping positions depending on the force, duration, tube geometry, rotor angle and braking profile.
Aspirating near the interface may increase access to selected cellular populations. It should not be assumed that every platelet population of interest is concentrated at the same depth or that the distribution remains identical across patients.
Does the aspiration pathway reach the intended cellular region?
The physician may intend to collect plasma immediately above the buffy coat, but the actual aspiration depth may be determined by needle length, port position, tube geometry, visualization, aspiration angle or an internal collection channel.
Technique becomes particularly important when the aspiration endpoint is subjective. Small differences in depth may alter platelet recovery, leukocyte differential and erythrocyte contamination.
Younger or reticulated platelets may be of biological interest, but their recovery should be measured rather than inferred from aspiration near the buffy coat. The system should demonstrate which platelet subpopulations are actually present at the selected collection depth.
What cellular population was the gel designed to separate?
A gel or physical separator can improve workflow consistency by creating a repeatable boundary between plasma and denser cellular fractions. The separator is therefore an active part of the cellular-selection design.
The relevant question is not whether gel technology is good or bad. It is whether the density boundary, centrifuge protocol and recovery method have been characterized for the biological product the physician intends to deliver.
Was only cellular quantity measured?
A final CBC or hematology analysis can establish platelet, erythrocyte and leukocyte counts. It does not independently establish platelet activation state, membrane integrity, aggregation response or other aspects of cellular function.
Platelet count, erythrocyte count, total leukocyte count and leukocyte differential describe the measurable cellular population.
Activation markers, morphology, aggregation and functional assays address questions that the final cell count cannot answer alone.
Does the resulting product match the treatment objective?
There is no single cellular profile that is automatically appropriate for every indication. A system may intentionally produce a leukocyte-poor product, a leukocyte-rich product or a preparation that retains selected mononuclear cells while limiting neutrophils.
The audit is whether that profile is intentional, measurable, reproducible and aligned with the physician's biological goal for the patient.
Convenience, consistency and appearance are valuable when they support the intended biology. The final measure is whether the system helps the physician deliver a reproducible cellular product aligned with the best possible patient outcome.
The PRP preparation is complete. Then another device, spin, filter, activator or concentration step is added.
The process looks more advanced. Is the biology better defined?
Added processing may intentionally change concentration, volume, fibrin structure, cellular composition, activation state or handling characteristics. Those changes may be useful, but each additional step creates another opportunity to alter the product in ways that extend beyond the advertised objective.
An extra spin may redistribute platelets into a smaller volume. Dehydration may increase measured concentration by removing fluid. Filtration or physical manipulation may change plasma proteins, cellular recovery or fibrin behavior. None of these changes is inherently beneficial or harmful.
A laboratory study may demonstrate that the product changed. A mechanistic explanation may describe why the change could matter. Neither result independently shows that patients experience better outcomes.
Platelets and neutrophils are not biologically static. Activation, injury or degranulation may begin during processing. A final cell count can describe what remains in the syringe, but it cannot independently account for every mediator that may already have been released into the plasma.
The question is not whether complexity is bad. It is whether the added complexity produces a demonstrated biological or clinical advantage, and whether that advantage justifies the additional cost, consumables, equipment and dependence on a proprietary workflow.
What does the added step measurably improve, what else does it change, and has either effect been connected to better patient outcomes?
Cells remaining in the syringe can be counted. Material already released through activation, injury or degranulation requires different testing.
An added processing step may create a product that is more concentrated, more structured, easier to handle or visually distinctive. The audit begins by separating that measurable change from the clinical benefit being proposed.
What specific problem is the added step intended to solve?
Added processing should begin with a clearly defined objective. Without that objective, it becomes difficult to determine whether the finished product is biologically improved or simply different.
A product may satisfy one of these objectives while creating tradeoffs in recovery, cellular state, plasma composition, handling time or reproducibility.
Did the step create more therapeutic material or redistribute what was already present?
A higher final concentration can result from increasing the number of platelets in the syringe, decreasing the fluid volume, or both. Those pathways do not necessarily produce the same total platelet dose.
The total number of platelets available for injection increases because fewer platelets remain outside the harvest.
Concentration may increase even when the total injected platelet population does not.
What happened to the platelets and leukocytes during the added step?
Platelets and leukocytes may respond to mechanical force, contact surfaces, temperature, transfer, agitation, osmotic change, filtration and prolonged handling. The magnitude and relevance of those responses depend on the complete device and protocol.
A hematology analysis may report the number of platelets, neutrophils, monocytes and erythrocytes remaining after processing.
Activation or cellular injury may release granule contents, inflammatory mediators, enzymes or other biological material before injection.
Platelet activation may be intentional when the clinical goal is to begin fibrin formation or mediator release before delivery. The concern is not activation itself. The concern is whether the timing, magnitude and reproducibility of that activation were measured.
Neutrophil activation may also alter the inflammatory character of the preparation through released enzymes, reactive species, cytokines or extracellular structures. The relevance depends on the indication, the cellular profile and the intended biological response.
Was the complete before-and-after product characterized?
A reliable evaluation should measure the preparation before and after the added step. Testing only the final product cannot identify what was gained, lost, activated or released during processing.
How far has the proposed benefit progressed through the evidence pathway?
Evidence that a device changes the product is important. It is not the same as evidence that the altered product improves patient outcomes.
Does the added complexity provide value that matters to the patient?
Added processing can introduce meaningful benefits. It can also introduce more handling, more transfers, more operator decisions and greater dependence on a proprietary workflow.
The audit question is whether the new cost and complexity are supported by independent evidence that the resulting product is biologically superior or produces better patient outcomes. A new proprietary step should address a defined need rather than rely on novelty alone to establish value.
The final audit is whether the proposed advantage justifies the added handling, time, cost, consumables and reliance on the manufacturer’s workflow.
The protocol was followed, but the preparation still did not look or behave as expected.
Was the variation caused by the operator, the patient, or the system’s tolerance for normal clinical conditions?
Reproducibility depends on more than staff training. Collection quality, centrifuge loading, tube construction, patient hematocrit, interface stability, post-spin handling and aspiration technique may all influence the final preparation.
Some failures are obvious. A tube breaks, the sample clots, the separation is disturbed, or the disposable cannot be used. Other changes are harder to recognize. The product may look acceptable while platelet recovery, leukocyte content, erythrocyte carryover or final dose has changed.
Mechanical separators, gel barriers and controlled collection pathways may reduce dependence on subjective aspiration and interface handling. Their value depends on whether the resulting product is both reproducible and aligned with the physician’s treatment objective.
A manually adjustable system may offer greater control over LP-PRP, monocyte-rich PRP or LR-PRP while becoming more dependent on operator judgment. A highly standardized system may reduce variability while producing a narrower range of biological outputs.
The audit is not whether standardization or flexibility is universally better. It is whether the system remains reliable under normal clinical use while preserving the biological choices required by the treatment plan.
Does your system reduce unwanted variability without also removing the clinical control you need?
A product may appear technically acceptable while dose, platelet recovery, leukocyte content or erythrocyte carryover has moved outside the intended range.
A reproducible PRP system should tolerate routine variation in patient blood characteristics, centrifuge loading, post-spin handling and trained operator technique without producing an unrecognized change in the final biological product.
How much deviation can occur before the final product changes?
A centrifuge cycle may reach completion even when the sample experienced vibration, minor imbalance, tube movement or a different acceleration and braking environment than intended. The absence of an alarm does not establish that the biological output was unaffected.
Unequal tube mass or position may increase vibration and alter the mechanical environment of the sample.
Breakage, leakage, stopper movement or structural failure can destroy the sample and interrupt the procedure.
Poor fit or inconsistent seating may change tube motion and separation behavior.
Nominal settings may not fully describe the mechanical history experienced by the cells.
A physical separator may improve consistency when it forms the validated boundary reliably.
Hidden variation is more difficult to manage than an obvious device failure.
Can the operator preserve the separation created by the centrifuge?
A reproducible gradient may be altered during tube removal, transport, resuspension or aspiration. Systems that depend on a fragile free interface may be sensitive to small handling differences.
Physical separators can reduce sensitivity to some forms of handling by stabilizing or defining the collection boundary. Their performance should be evaluated by the consistency and biological profile of the product they produce.
Does the system remain reliable across different patient blood characteristics?
A standardized centrifuge protocol is applied to blood that is not standardized. Patient-dependent differences may change layer proportions, interface position, viscosity, sedimentation and the accessibility of the intended fraction.
Interface position and available plasma volume may shift between patients.
The same percentage recovery can still produce a different final platelet dose.
A fixed collection boundary may not produce the same leukocyte differential in every patient.
The practical effect should be characterized rather than assumed to be negligible.
Difficult collection, clotting or delayed processing may become consequential.
The system should provide a defined response rather than depend on improvised operator judgment.
Can the operator recognize when the biological product has changed?
Deviations can occur at any point in the workflow. Some clearly prevent use of the preparation. Others allow the procedure to continue while leaving uncertainty about the final product.
- Broken or leaking disposable
- Inadequate blood collection
- Visible clotting
- Severely disturbed separation
- Mechanical malfunction
- Insufficient usable product
Does the system improve consistency while preserving the biological choices that matter?
Gel barriers, valves, collection ports and mechanical separators may establish a repeatable collection boundary. This can reduce dependence on visual judgment, post-spin handling and subjective aspiration depth.
The relevant audit is whether the resulting product is reproducible, well characterized and aligned with the physician’s intended treatment.
A physical separator may improve repeatability by reducing technique-dependent decisions.
Greater flexibility may support different treatment goals while increasing dependence on technique.
How are preventable failures limited and meaningful deviations identified?
Reproducibility improves when the workflow controls high-risk variables, makes errors visible and defines what the operator should do when the process falls outside its intended range.
Specify acceptable collection, sample condition, timing and processing requirements.
Reduce variation in the mechanical environment.
Use handling methods and device designs that tolerate routine trained movement.
Limit subjective collection variability where manual aspiration is used.
Identify when a preparation should be questioned, repeated or discarded.
Track replacement kits, repeat draws, disturbed separations and processing deviations.
A robust system should reduce preventable failures, make meaningful deviations detectable and preserve the clinical choices required to align the preparation with the patient and treatment objective.
Would you choose the same PRP system today?
The system may have been the easiest choice when it entered the practice. Is it still the best choice for the biology you want to deliver?
A strong representative can improve training, availability, troubleshooting, inventory management and account support. Those contributions are meaningful and may directly improve the clinical workflow.
The credibility of the representative or manufacturer may also reduce the likelihood that the underlying technology receives an independent biological and engineering review. Familiarity can become a substitute for comparison.
A system may remain in a practice because it is available, familiar and operationally convenient even when alternative platforms offer different dose capacity, recovery, cellular control, reproducibility, evidence or cost.
Existing capital equipment can reinforce that decision. A practice may avoid reconsidering its system because the current centrifuge is already owned or was placed without charge. Yet the centrifuge is acquired once, while disposable cost and biological performance recur with every patient.
A quality centrifuge may represent a modest expense when distributed across routine procedure volume. In some practices, that capital cost may be recovered across a relatively small number of procedures. The more important comparison is the total cost and performance of the complete workflow over time.
Newer does not automatically mean better, and established does not automatically mean outdated. The audit is whether the current system would still be selected after its biological performance, evidence, workflow, support and total cost were compared independently with credible alternatives.
If the representative, manufacturer name, existing centrifuge and purchasing relationship were removed from the decision, would you still choose the same system?
Trust in the representative may establish confidence in the support. It does not independently establish confidence in the biological product.
A PRP system may enter a practice through an existing relationship, familiar manufacturer, convenient purchasing pathway or no-charge equipment placement. Those factors may support adoption without independently establishing that the technology is the best biological or economic fit.
How did the system enter the practice?
A system may be adopted because it was independently researched, but it may also enter through an existing vendor, bundled account relationship, equipment placement, staff preference or product demonstration.
None of these are inherently poor reasons to consider a system. The audit is whether they were accompanied by an objective comparison of the biological product and long-term economics.
Were the easiest variables to compare allowed to dominate the decision?
Initial system evaluations often emphasize preparation time, ease of use, syringe volume, kit price and representative support. Those factors matter, but they do not fully describe the biological treatment.
- Kit price
- Preparation time
- Ease of use
- Syringe volume
- Representative availability
- Equipment placement
- Injected platelet dose
- Recovery methodology
- Cellular profile
- Platelet activation and function
- Patient-specific adaptability
- Independent evidence
Has the system earned its place through measured performance?
A preparation can be technically usable without being biologically optimized. Patients may improve, the product may look acceptable and the workflow may continue without the practice knowing whether another platform would provide a more appropriate dose, cell profile, recovery or cost.
Is existing equipment preventing a better comparison?
A centrifuge already sitting in the office can become an anchor for future purchasing decisions. The practice may continue using a more expensive disposable or accept limited biological performance because replacing the capital equipment feels unnecessary.
A quality centrifuge may be amortized across routine procedure volume. In some practices, the investment may be recovered across a relatively small number of cases, particularly when the alternative system uses higher-cost disposables.
No-charge placement may be an efficient way to introduce a validated system without requiring a capital budget. Its value should be evaluated alongside disposable pricing, purchasing commitments, service terms, expected procedure volume and biological performance.
What does the complete system cost over time?
Kit price alone does not describe the total economic effect of a PRP system. Capital, disposables, failures, workflow and biological limitations should be evaluated together.
Is the representative being evaluated separately from the technology?
A strong representative may be one of the most valuable parts of the account. The representative can deliver excellent support even when the underlying platform is not the best fit for the physician’s biological goals.
- Training
- Case support
- Troubleshooting
- Inventory management
- Responsiveness
- Continuity of service
- Dose capacity
- Platelet recovery
- Cellular profile
- Platelet function
- Reproducibility
- Independent evidence
Would the decision survive removal of the brand and sales relationship?
Market presence demonstrates successful adoption. It does not, by itself, demonstrate superior biological performance. A newer system should also be required to earn confidence through validation rather than novelty.
A blinded comparison asks the physician to remove the manufacturer name, representative, installed equipment and marketing language before comparing the variables that matter.
Do not allow a one-time capital expense, familiar workflow or trusted relationship to prevent evaluation of a recurring clinical and economic decision.
How well do you know your PRP system?
Confidence grows as uncertainty is removed.
This audit has examined dose, separation, cellular composition, processing, reproducibility, economics and evidence. Some questions may have had immediate answers. Others may have exposed assumptions that had never been tested.
The purpose was not to identify one universally superior system. It was to apply the same scientific curiosity to PRP preparation that physicians apply to every other part of patient care.
A well-characterized system produces a biological product that is understood, reproducible and supported by evidence appropriate for the clinical decisions being made.
After completing this audit, which questions about your system can you answer with evidence, and which still deserve investigation?
It is the cumulative result of understanding the patient input, processing pathway, final product, reproducibility, evidence and clinical purpose.
A system audit does not end by assigning a passing or failing grade. It ends by distinguishing what is known, what remains uncertain and which unanswered questions are important enough to investigate.
Which questions can the practice already answer?
The starting cellular population and volume entering the system are known.
The preparation reaching the syringe has been measured rather than inferred.
The complete mechanical and handling history is understood.
The practice knows how much variation occurs between patients, operators and procedures.
Manufacturer statements, laboratory findings and clinical outcomes are not treated as interchangeable.
Capital, disposables, failures, staff burden and biological limitations are considered together.
What is measured, and what is assumed?
- Baseline and final cell counts
- Measured platelet recovery
- Known centrifuge protocol
- Documented operator variability
- Independent product characterization
- Clinical claims supported by outcomes
- The product looks correct
- The workflow is routinely used
- The manufacturer is well known
- The platelet concentration is estimated
- The cellular profile is inferred
- Patient improvement is attributed to the system
Which unanswered questions deserve priority?
Not every unknown requires an immediate laboratory program. The highest-value questions are the ones most likely to change the biological product, clinical decision, workflow reliability or economic value of the system.
When should the system be reviewed again?
New findings may strengthen or weaken confidence in the current workflow.
Innovation should be compared objectively rather than accepted or rejected based on novelty.
Any meaningful workflow change may alter reproducibility or final product characteristics.
Real-world deviations may reveal limitations not apparent during initial adoption.
A product appropriate for one treatment goal may not be ideal for another.
The total-value comparison may change even when the technology does not.
What would a practical validation process look like?
A useful validation process can begin with a small number of representative procedures. The objective is not to reproduce a manufacturer’s entire laboratory program. It is to understand whether the system performs in the practice as expected.
Establish the desired dose, volume and cellular profile before evaluating the system.
Use baseline and final testing to calculate dose, recovery and composition.
One ideal preparation cannot establish routine reproducibility.
Real-world reliability includes what happens when the workflow does not proceed perfectly.
Remove brand, familiarity and sales relationships from the biological comparison.
System evaluation should remain a clinical process rather than a one-time purchasing event.
The goal of this audit is not to identify a universally superior system. It is to help physicians understand the biological product they deliver well enough to match it intentionally to the needs of each patient.
Which assumptions are supported by evidence, and which are supported by habit?
The goal is not to tell you which system to buy. It is to help you recognize whether the system you use consistently produces the biology you intend to deliver.
Schedule Your Independent PRP System Review